Barrington Research Increases DENTSPLY SIRONA (NASDAQ:XRAY) Price Target to $17.00

DENTSPLY SIRONA (NASDAQ:XRAY) had its price objective upped by Barrington Research from $14.00 to $17.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research’s price objective would suggest a potential upside of 27.82% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Barclays started coverage on DENTSPLY SIRONA in a research note on Monday, December 8th. They set an “underweight” rating and a $12.00 price objective on the stock. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their price target for the company from $13.00 to $17.00 in a report on Thursday, February 19th. Mizuho raised their price target on DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research report on Wednesday, January 21st. Finally, Zacks Research lowered shares of DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a report on Monday, November 10th. Three equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, DENTSPLY SIRONA currently has a consensus rating of “Hold” and a consensus price target of $14.42.

DENTSPLY SIRONA Trading Down 7.1%

Shares of XRAY opened at $13.30 on Monday. The stock has a market capitalization of $2.66 billion, a PE ratio of -4.43, a P/E/G ratio of 1.68 and a beta of 0.97. The company’s fifty day moving average is $12.52 and its 200 day moving average is $12.47. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. DENTSPLY SIRONA has a fifty-two week low of $9.85 and a fifty-two week high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The business had revenue of $961.00 million during the quarter, compared to analysts’ expectations of $926.40 million. During the same period in the previous year, the business earned $0.26 earnings per share. The business’s quarterly revenue was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts expect that DENTSPLY SIRONA will post 1.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Gregory T. Lucier sold 82,200 shares of DENTSPLY SIRONA stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.52% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On DENTSPLY SIRONA

A number of hedge funds have recently added to or reduced their stakes in XRAY. Daiwa Securities Group Inc. boosted its position in DENTSPLY SIRONA by 2.9% during the 4th quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier’s stock valued at $306,000 after acquiring an additional 767 shares in the last quarter. Arizona State Retirement System lifted its stake in shares of DENTSPLY SIRONA by 1.4% during the 3rd quarter. Arizona State Retirement System now owns 58,952 shares of the medical instruments supplier’s stock worth $748,000 after purchasing an additional 807 shares during the last quarter. True Wealth Design LLC boosted its position in DENTSPLY SIRONA by 49.7% during the third quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 1,181 shares in the last quarter. Sivia Capital Partners LLC boosted its position in DENTSPLY SIRONA by 5.3% during the third quarter. Sivia Capital Partners LLC now owns 25,774 shares of the medical instruments supplier’s stock valued at $327,000 after purchasing an additional 1,293 shares in the last quarter. Finally, Empowered Funds LLC grew its stake in DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 1,320 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors.

DENTSPLY SIRONA News Summary

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Director buying: Gregory T. Lucier significantly increased his stake in Dentsply Sirona, purchasing 27,555 shares on March 2 at ~$14.24 and 22,445 shares on March 3 at ~$14.03 (bringing his reported holdings to ~50,000 shares). Large insider purchases are often viewed as a bullish signal of management confidence. SEC Form 4
• Positive Sentiment: Barrington Research raised its price target to $17 and maintained an “outperform” rating — a bullish analyst action that implies meaningful upside from current levels and can support buying interest. Barrington Research PT Raise
• Neutral Sentiment: Mizuho raised its price target to $16 but kept a “neutral” rating — a PT lift that helps sentiment but the unchanged rating tempers the positive impact. Mizuho PT Update TickerReport
• Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference on March 10 — a scheduled investor event that provides an opportunity for management to update guidance and interact with analysts (near-term catalyst if new commentary or data are released). Conference Notice
• Neutral Sentiment: Analyst coverage/targets: Smaller media posts also reported price-target bumps (AmericanBankingNews noted PTs raised to $13 and $14). These incremental upgrades help sentiment but are mixed in magnitude. PT to $13 PT to $14
• Neutral Sentiment: Fundamental note: A Zacks piece flagged international revenue trends as an area to watch; investors assessing XRAY should consider geographic growth dynamics versus company guidance/analyst models. Zacks Analysis
• Neutral Sentiment: Short-interest data appears anomalous (reports show zero shares / NaN changes), suggesting a reporting error rather than a genuine short-squeeze or relief — treat the short-interest updates cautiously. (No reliable link; data appears inconsistent in the filings.)

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.